IND-Enabling Safety Evaluation of mRNA-LNP Cancer Therapeutic
Time: 3:00 pm
day: Day One
Details:
- General consideration for Tox assessment of mRNA-LNP
- Safety evaluation of mRNA-LNP in a context of cancer immunotherapy
- Enabling intratumoral administration
